Want to see LH full AI Analyst Report?
Operating Income by Segment
Shows profitability across different business units, highlighting which areas drive earnings and where there might be challenges or opportunities for growth.
Diagnostics and Drug Development operating income have shifted from pandemic volatility into a clear rebound since 2023, driving margin expansion that helped management raise 2026 guidance; Drug Development (BLS) gains are supported by a strong $8.7B backlog and healthy book‑to‑bill, while Diagnostics benefits from improving volume/price mix and new product launches. General corporate costs remain a recurring, asymmetric drag and elevated leverage plus timing-driven FCF weakness are the main risks to watch despite improving segment-level momentum.
LH Operating Income by Segment
| Date | Diagnostics | Drug Development | General Corporate Expenses |
|---|---|---|---|
| Sep 30, 2026 | $491.60M | $159.00M | -$80.60M |
| Jun 30, 2026 | $522.60M | $142.20M | -$76.10M |
| Mar 31, 2026 | $458.70M | $120.70M | -$71.50M |
| Dec 31, 2025 | $419.20M | $136.10M | -$67.60M |
| Sep 30, 2025 | $450.40M | $132.20M | -$69.30M |
| Jun 30, 2025 | $482.80M | $123.30M | -$74.50M |
| Mar 31, 2025 | $427.50M | $106.90M | -$65.40M |
| Dec 31, 2024 | $359.50M | $130.80M | -$67.10M |
| Sep 30, 2024 | $387.40M | $120.90M | -$67.20M |
| Jun 30, 2024 | $441.50M | $107.40M | -$69.00M |
| Mar 31, 2024 | $417.90M | $99.90M | -$65.00M |
| Dec 31, 2023 | $353.70M | $109.00M | -$67.80M |
| Sep 30, 2023 | $386.30M | $109.00M | -$71.40M |
| Jun 30, 2023 | $409.70M | $104.60M | -$177.90M |
| Mar 31, 2023 | $441.50M | $123.90M | -$71.90M |
| Dec 31, 2022 | $387.00M | $208.50M | -$85.60M |
| Sep 30, 2022 | $439.80M | $210.70M | -$61.40M |
| Jun 30, 2022 | $515.60M | $213.30M | -$72.80M |
| Mar 31, 2022 | $683.10M | $168.60M | -$57.70M |
| Dec 31, 2021 | $775.90M | $205.70M | -$84.90M |
| Sep 30, 2021 | $774.90M | $226.10M | -$93.90M |
| Jun 30, 2021 | $663.20M | $221.10M | -$44.40M |
| Mar 31, 2021 | $991.60M | $234.10M | -$43.80M |
| Dec 31, 2020 | $1.23B | $248.40M | -$53.30M |
| Sep 30, 2020 | $1.00B | $209.70M | -$57.80M |
| Jun 30, 2020 | $308.80M | $112.70M | -$40.80M |
| Mar 31, 2020 | $254.20M | $150.80M | -$39.10M |
| Dec 31, 2019 | $277.10M | $183.20M | -$38.30M |
| Sep 30, 2019 | $296.30M | $175.00M | -$40.80M |
| Jun 30, 2019 | $345.40M | $141.70M | -$40.20M |
| Mar 31, 2019 | $310.40M | $138.00M | -$37.00M |
| Dec 31, 2018 | $279.30M | $153.50M | -$37.90M |
| Sep 30, 2018 | $331.50M | $131.30M | -$33.60M |
| Jun 30, 2018 | $376.00M | $123.40M | -$35.90M |
| Mar 31, 2018 | $364.00M | $108.00M | -$36.30M |
| Dec 31, 2017 | $357.00M | $110.90M | -$35.20M |
| Sep 30, 2017 | $374.30M | $93.80M | -$36.20M |
| Jun 30, 2017 | $375.50M | $88.50M | -$32.90M |
| Mar 31, 2017 | $341.80M | $68.10M | -$33.20M |
